The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen

Anticancer Research

Volumn 32, Issue 4, 2012, Pages 1547-1553

  Kim, Jin Won ^a   Im, Seock Ah ^a,b   Kim, Miso ^a   Cha, Yongjun ^a   Lee, Kyung Hun ^a   Keam, Bhumsuk ^a   Kim, Min A ^a,b   Han, Sae Won ^a,b   Oh, Do Youn ^a,b   Kim, Tae You ^a,b   Kim, Woo Ho ^a,b   Bang, Yung Jue ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

FISH; FOLFOX 6 regimen; Gastric cancer; HER2 positivity; Transtuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; FLUOROURACIL; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RECURRENCE; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84859992169     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006. (Pubitemid 46655601)
2. Okines AF, Norman AR, McCloud Pet, Kang YK and Cunningham D: Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20: 1529-1534, 2009.
3. Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, Oh DY, Kim JH, Lee DS, Kim TY and Bang YJ: The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 272: 296-306, 2008.
4. Kim SY, Kim HP, Kim YJ, Oh DY, Im SA, Lee D, Jong HS, Kim TY and Bang YJ: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 32: 89-95, 2008. (Pubitemid 351176065)
5. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K and Tanaka Y: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59: 795-805, 2006. (Pubitemid 46440603)
6. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Uhle M, Rüschoff J and Kang YK; ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
7. Tateishi M, Toda T, Minamisono Y and Nagasaki S: Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. Surg Oncol 49: 209-212, 1992.
8. Sasano H, Date F, Imatani A, Asaki S and Nagura H: Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 24: 584-589, 1993. (Pubitemid 23162224)
9. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Miyazaki I, Endou Y, Tanaka M and Sasaki T: Evaluation of immunoreactivity for ERBB2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res 51: 1034-1038, 1991.
10. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K and Isola J: Amplification of HER-2 in gastric carcinoma: association with topoisomerase Ha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005. (Pubitemid 40309309)
11. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH and Sepulveda AR: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51: 1371-1379, 2006. (Pubitemid 44315804)
12. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW and Heiss MM: C-ERBB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor associated protease systems. J Clin Oncol 18: 2201-2209, 2000. (Pubitemid 30350211)
13. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J and Henkel T: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805, 2008. (Pubitemid 351724903)
14. Cunningham D, Starling N, Rao S Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-46, 2008.
15. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G and McCloud PI: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20: 666-673, 2009.
16. Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Kim WH and Bang YJ: Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 8: 148, 2008.
17. Gravalos C and Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529, 2008.
18. Kim MA, Jung EJ, Lee HS Ue HE, Jeon YK, Yang HK and Kim WH: Evaluation of HER-2 gene Status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 38: 1386-1393, 2007. (Pubitemid 47247482)
19. Bang YJ, Chung H, Xu F. Lordick, A. Sawaki, N. Al-Sakaff, O. Lipatov, C. See, J. Rueschoff, and E. Van Cutsem: Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 27: 15s, 2009. (suppl; abstr 4556)
20. Hanna WM and Kwok K: Chromogenic in situ hybridization: a viable alternative to fluorescence in situ hybridization in the HER2 testing algorithm. Mod Pathol 19: 481-487, 2006.
21. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, Tsuneyama K and Takano Y: Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol 60: 273-277, 2007. (Pubitemid 46447742)